Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by MountainMasteron Jul 11, 2018 2:08pm
169 Views
Post# 28301240

News and Results

News and Results I spoke with Mike Liggett on Tuesday morning. He informed me and others that took the time to contact him, that the pharmacokinetic results and other related news will be released sometime this week. The company has released news on Wednesdays in the past so I suspect a lot of investors thought it would be today as well, hence the solid trading yesterday.
I personally feel that releasing news on Friday is not the greatest idea so my guess would be tomorrow, Thursday. 
In no way am I management, I'm just an investor that took the time to call to get some information. It clearly states in the last news release that the results would be released in the weeks to come so this week is the week. 
No he didn't say anything about the results or news but speaking with him was like speaking to a 16 year old who just got their drivers licence, you could hear and feel the excitement.

Contact info which is public:

Mike Liggett
Chief Financial Officer
778 802-9806
liggett@icotherapeutics.com
<< Previous
Bullboard Posts
Next >>